Cargando…
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
Our analysis of the tumors of 57 women with metastatic breast cancer with next generation sequencing (NGS) demonstrates that each patient's tumor is unique in its molecular fingerprint. We observed 216 somatic aberrations in 70 different genes, including 131 distinct aberrations. The most commo...
Autores principales: | Wheler, Jennifer J., Parker, Barbara A., Lee, Jack J., Atkins, Johnique T., Janku, Filip, Tsimberidou, Apostolia M., Zinner, Ralph, Subbiah, Vivek, Fu, Siqing, Schwab, Richard, Moulder, Stacy, Valero, Vicente, Schwaederle, Maria, Yelensky, Roman, Miller, Vincent A., Stephens, M Philip J., Meric-Bernstam, Funda, Kurzrock, Razelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058010/ https://www.ncbi.nlm.nih.gov/pubmed/24811890 |
Ejemplares similares
-
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016) -
Multiple gene aberrations and breast cancer: lessons from super-responders
por: Wheler, Jennifer J., et al.
Publicado: (2015) -
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014) -
Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015) -
Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
por: Wheler, Jennifer, et al.
Publicado: (2013)